Efficacy of recombinant Human Brain Natriuretic Peptide combined with Sacubitril Valsartan in the Treatment of hypertensive patients with acute Heart Failure
Objective To analyze the efficacy of recombinant human brain natriuretic peptide(rh-BNP)combined with sacubitril and valsartan in the treatment of hypertension with acute heart failure(AHF)and its impact on neuroendocrine indicators.Methods A total of 150 hypertensive patients with AHF admitted to Anyang People's Hospital from January 2021 to February 2023 were randomly divided into control group and observation group,with 75 cases in each group.The control group was treated with sacubitril valsartan,while the observation group was treated with rh-BNP combined with sacubitril valsartan.The levels of cardiac function,neuroendocrine indicators,efficacy,and incidence of adverse reactions between two groups after treatment were compared.Results After treatment,the left ventricular end diastolic diameter,left ventricular end systolic diameter,norepinephrine,adrenaline,angiotensin Ⅱ,and aldosterone in the observation group were all lower than those in the control group.The left ventricular peak filling rate and left ventricular ejection fraction in the observation group were significantly higher than those in the control group,and the differences were statistically significant(P＜0.05);The effective rate of treatment in the observation group(97.33%)was higher than that in the control group(86.67%),and the differences were statistically significant(P＜0.05);There was no statistically significant difference in adverse reactions between the two groups(13.33%vs 10.67%)(P＞0.05).Conclusion Compared with sacubitril valsartan,the combination of rh-BNP in the treatment of hypertensive patients with AHF can effectively improve heart function,reduce neuroendocrine indicators,and is worthy of clinical application.
hypertensionacute heart failurerecombinant human brain natriuretic peptidesacubitril valsartanneuroendocrinecurative effect
万方数据
维普
